CN: 32-1845/R
ISSN: 2095-6975
引用本文:
0
ZHANG Rui-Wen. Traditional Chinese medicine: research and development, globalization, and regulation[J]. 中国天然药物英文, 2017, 15(1): 1-3

Traditional Chinese medicine: research and development, globalization, and regulation

ZHANG Rui-Wen1,2
1 Associate Editor-In-Chief, Chinese Journal of Natural Medicines, Nanjing 210009, China;
2 Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
摘要:
关键词:   
收稿日期: 2017-01-10
ZHANG Rui-Wen, Tel:1-806-4149248; Fax:1-806-3564034; E-mail:ruiwen.zhang@ttuhsc.edu
相关功能
PDF(305 KB) Free
打印本文
把本文推荐给朋友
作者相关文章
ZHANG Rui-Wen 在本刊中的所有文章
参考文献:
[1] Lin Y, Wu ZA, Shao ML. Evolution of the registration regulations for proprietary Chinese medicines in China [J]. Chin J Nat Med, 2017, 15(1): 4-11.
[2] Graham D. Regulation of proprietary traditional Chinese medicines in Australia [J]. Chin J Nat Med, 2017, 15(1): 12-14.
[3] Thelingwani R, Masimirembwa C. Evaluation of herbal medicines: value addition to traditional medicines through metabolism, pharmacokinetic and safety studies [J]. Curr Drug Metab, 2014, 15(10): 942-529.
[4] Xue CC, Zhang AL, Greenwood KM, et al. Traditional Chinese medicine: an update on clinical evidence [J]. J Altern Complement Med, 2010, 16(3): 301-312.
[5] Wu WY, Hou JJ, Long HL, et al. TCM-based new drug discovery and development in China [J]. Chin J Nat Med, 2014, 12(4): 241-250.
[6] Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application [J]. Chin J Nat Med, 2013, 11(2): 110-120.
[7] Zi T, Yu D. A network pharmacology study of Sendeng-4, a Mongolian medicine [J]. Chin J Nat Med, 2015, 13(2): 108-118.
[8] Yan SK, Liu RH, Jin HZ, et al. "Omics" in pharmaceutical research: overview, applications, challenges, and future perspectives [J]. Chin J Nat Med, 2015, 13(1): 3-21.
[9] Uzuner H, Fan TP, Dias A, et al. Establishing an EU-China consortium on traditional Chinese medicine research [J]. Chin Med, 2010, 5: 42.
[10] Wu KM, Ghantous H, Birnkrant DB. Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States [J]. Food Chem Toxicol, 2008, 46(8): 2606-2610.
[11] Walker LA, Budd S. UK: the current state of regulation of complementary and alternative medicine [J]. Complement Ther Med, 2002, 10(1): 8-13.
[12] Carlton AL, Bensoussan A. Regulation of complementary medicine practitioners in Australia: Chinese medicine as a case example [J].Complement Ther Med, 2002, 10(1): 20-26.
[13] Smith A, Jogalekar S, Gibson A. Regulation of natural health products in Canada [J]. J Ethnopharmacol, 2014, 158(Pt B): 507-510.
[14] Sammons HM, Gubarev MI, Krepkova LV, et al.Herbal medicines: challenges in the modern world. Part 2. European Union and Russia [J]. Expert Rev Clin Pharmacol, 2016, 9(8): 1117-1127.
[15] Valdivia-Correa B, Gómez-Gutiérrez C, Uribe M, et al. Herbal medicine in Mexico: a cause of hepatotoxicity [J]. A Critical Review [J]. Int J Mol Sci, 2016, 17(2): 235.
[16] Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps [J]. Front Pharmacol, 2015,6: 72.
[17] Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia [J]. Drug Saf, 2012, 35(12): 1091-1097.
[18] Fan TP, Deal G, Koo HL, et al.Future development of global regulations of Chinese herbal products [J]. J Ethnopharmacol, 2012, 140(3): 568-586.
[19] Siow YL, Gong Y, Au-Yeung KK, et al.Emerging issues in traditional Chinese medicine [J]. Can J Physiol Pharmacol, 2005, 83(4): 321-34.
[20] Zhang RW. Artemisinin (Qinghaosu), Nobel Prize, anti-malaria, and beyond [J]. Chin J Nat Med,2016, 14(1): 1-2.
[21] Wang XB. Pharmaceutical innovation and advancement of clinical therapy and public health: enlightenment from artemisinin development [J]. Chin J Nat Med, 2016, 14(1): 3-4.Jiang Y, Xia JP, Yang JH, et al. Guidelines and strategy of the International Conference of Harmonization (ICH) and its member states to overcome existing impurity control problems for antibiotics in China [J]. Chin J Nat Med, 2015, 13(7): 498-506.